Disease extent, previous treatment, and details of mustine treatment in 20 children with LCH
|
Patient no | Sex | Extent of skin disease (% of body surface) | Involvement of other organs | Treatment prior to mustine | Number and duration of mustine courses (wk) | Time to response of skin rash (wk) |
Side effects of mustine |
| 1 | M | 3 | LN | VB, VP16, HDMP | 2 (12/4) | 4 | 0 |
| 2 | M | 32 | B, DI, G | VP16 | 1 (12) | 4 | 0 |
| 3 | F | 23 | — | — | 3 (3/3/3) | 2 | 0 |
| 4 | M | 9 | B, DI, G | HDMP, VP16 | 3 (2/2/1) | 2 | 0 |
| 5 | F | 7 | B,G | — | 2 (36/8) | 4 | 0 |
| 6 | M | 7 | B, LN, G | P, AZ, VP16, RxT, VB | 1 (6) | >6 | 0 |
| 7 | F | 21 | B, DI | P, VB | 2 (28/4) | 4 | 0 |
| 8 | M | 15 | B, DI, L, G | P | 1 (4) | 2–3 | 0 |
| 9 | M | 26 | — | — | 1 (12) | 4 | 0 |
| 10 | M | 24 | B | P | 2 (16/4) | 6 | 0 |
| 11 | M | 15 | B, BM, GI, G | HDMP, 6MP, VB, VP16, CsA | 1 (4) | 4 | 0 |
| 12 | M | 11 | B, DI, L, G, CNS | VB | 1 (20) | 2–3 | 0 |
| 13 | M | 11 | B, DI, L, G | P, VP16 | 3 (6/4/1) | 1–2 | Irritative dermatitis |
| 14 | M | 10 | DI, L, CNS | P | 1 (12) | 1 | 0 |
| 15 | M | 15 | DI, LN, G | — | 2 (4/4) | 4 | 0 |
| 16 | F | 15 | B | — | 1 (12) | 2–3 | 0 |
| 17 | M | 9 | B, DI, BM, L | VC, P | 2 (4/4) | 1 | 0 |
| 18 | M | 50 | B, BM, GI, G, C, LN | VP16, HDMP, VB, MTX | 3 (8/4/4) | 2–4 | Irritative dermatitis |
| 19 | M | 8 | B, DI, GI, L, G | HDMP | 1 (20) | 3 | 0 |
| 20 | F | 16 | B | P | 1 (10) | 1 | 0 |
LN, lymph node; B, bone; DI, diabetes insipidus; G, gingiva; L, lung; BM, bone marrow; GI, gastrointestinal tract; C, conjunctival; VB, vinblastine; HDMP, high dose methylprednisolone; VP16, etoposide; P, prednisolone; AZ, azathioprine; RxT, radiotherapy; 6MP, 6-mercaptopurine; CsA, cyclosporin A; VC, vincristine; MTX, methotrexate.